Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Argus Health
AstraZeneca
Farmers Insurance
Queensland Health
US Department of Justice
Johnson and Johnson
Deloitte
Baxter

Generated: November 19, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022434

« Back to Dashboard

NDA 022434 describes ARGATROBAN IN SODIUM CHLORIDE, which is a drug marketed by Eagle Pharms, Gland Pharma Ltd, and Sandoz, and is included in three NDAs. It is available from three suppliers. There are two patents protecting this drug. Additional details are available on the ARGATROBAN IN SODIUM CHLORIDE profile page.

The generic ingredient in ARGATROBAN IN SODIUM CHLORIDE is argatroban. There are eleven drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the argatroban profile page.
Summary for 022434
Tradename:ARGATROBAN IN SODIUM CHLORIDE
Applicant:Eagle Pharms
Ingredient:argatroban
Patents:2
Formulation / Manufacturing:see details
Pharmacology for NDA: 022434
Mechanism of ActionThrombin Inhibitors
Suppliers and Packaging for NDA: 022434
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ARGATROBAN IN SODIUM CHLORIDE argatroban INJECTABLE;INTRAVENOUS 022434 NDA Sandoz Inc 0781-3314 0781-3314-95 10 CARTON in 1 CARTON (0781-3314-95) > 1 VIAL, SINGLE-USE in 1 CARTON (0781-3314-91) > 50 mL in 1 VIAL, SINGLE-USE
ARGATROBAN IN SODIUM CHLORIDE argatroban INJECTABLE;INTRAVENOUS 022434 NDA Sandoz Inc 0781-9314 0781-9314-95 10 CARTON in 1 CARTON (0781-9314-95) > 1 VIAL, SINGLE-USE in 1 CARTON (0781-9314-91) > 50 mL in 1 VIAL, SINGLE-USE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INTRAVENOUSStrength50MG/50ML (1MG/ML)
Approval Date:Jun 29, 2011TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Sep 26, 2027Product Flag?YSubstance Flag?Delist Request?
Patented Use:METHOD OF TREATING THROMBOSIS
Patent:➤ Try a Free TrialPatent Expiration:Sep 26, 2027Product Flag?YSubstance Flag?Delist Request?
Patented Use:METHOD OF TREATING AN ARGATROBAN TREATABLE CONDITION

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Cantor Fitzgerald
QuintilesIMS
Cerilliant
Merck
Chinese Patent Office
Baxter
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.